Develops anti-cancer stem cell therapeutics
Company profile
Website
CEO
John A. Lewicki
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
383572512
Latest filings (excl ownership)
15-12B
Securities registration termination
3 May 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Apr 19
8-K
Completion of Acquisition or Disposition of Assets
23 Apr 19
25-NSE
Exchange delisting
23 Apr 19
8-K
Submission of Matters to a Vote of Security Holders
17 Apr 19
Latest ownership filings
SC 13D/A
OncoMed Pharmaceuticals Inc
26 Apr 19
4
Alicia J. Hager
23 Apr 19
4
JONATHAN D ROOT
23 Apr 19
4
JACK W LASERSOHN
23 Apr 19
4
John A. Lewicki
23 Apr 19
4
DEEPIKA PAKIANATHAN
23 Apr 19
4
Yvonne Li
23 Apr 19
4
Robert Stagg
23 Apr 19
4
PERRY A KARSEN
23 Apr 19
SC 13D
OncoMed Pharmaceuticals Inc
15 Mar 19
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|